Advances in ventilator-associated pneumonia: from pathophysiology to precision management
-
By
-
Anahita Rouzé
-
Ignacio Martin-Loeches
-
Jean-François Timsit
-
July 8, 2026
-
Clinical Scorecard: Progress in Understanding and Managing Ventilator-Associated Pneumonia: Insights from Pathophysiology to Tailored Approaches
At a Glance
| Category | Detail |
|---|
| Condition | Ventilator-Associated Pneumonia (VAP) |
| Key Mechanisms | Disruption of respiratory microbiome and host immune status due to mechanical ventilation and antibiotic exposure. |
| Target Population | Critically ill patients requiring invasive mechanical ventilation. |
| Care Setting | Intensive Care Unit (ICU) |
Key Highlights
- VAP is associated with substantial morbidity and mortality.
- Early antibiotic therapy does not consistently improve outcomes.
- The respiratory microbiome plays a crucial role in VAP susceptibility.
- Antimicrobial stewardship is essential to preserve microbiome homeostasis.
- Rapid molecular diagnostics can improve targeted therapy but face implementation challenges.
Guideline-Based Recommendations
Diagnosis
- Utilize syndromic multiplex PCR panels for rapid diagnosis of VAP.
Management
- Optimize antibiotic therapy by minimizing unnecessary exposure and considering delayed initiation until microbiological confirmation.
Monitoring & Follow-up
- Therapeutic drug monitoring in both serum and alveolar fluid is recommended, though underexplored.
Risks
- Inappropriate antibiotic use can lead to increased VAP incidence and mortality.
Patient & Prescribing Data
Patients with suspected VAP in the ICU.
Consider immune-phenotype-guided therapy for septic patients with VAP.
Clinical Best Practices
- Implement structured antibiotic stewardship frameworks.
- Promote continuous access to rapid diagnostics.
- Encourage clinicians to confidently interpret diagnostic results.
Related Resources & Content
